Welcome to our dedicated page for Journey Medical Corporation news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical Corporation stock.
Journey Medical Corporation (symbol: DERM) is a commercial stage pharmaceutical company dedicated to the development and commercialization of products designed to treat dermatological conditions. With a diverse portfolio that includes eight branded and three authorized generic prescription drugs marketed in the United States, Journey Medical is committed to improving the quality of life for patients with skin conditions.
Among the well-known products in their lineup are Qbrexza, a topical treatment for excessive underarm sweating, Accutane, a potent medication for severe acne, Amzeeq, a foam treatment for acne vulgaris, and Exelderm, an antifungal solution. These products highlight the company's dedication to addressing various dermatological needs.
Recently, Journey Medical secured additional capital to support general corporate purposes, including funding for the potential launch of DFD-29. This demonstrates their strategic effort to expand their product offerings and enhance their market presence.
The company is proactive in maintaining transparent communication with its stakeholders. They have scheduled a conference call on March 21, 2024, to discuss financial results and provide a corporate update. Furthermore, another conference call is set for May 13, 2024.
Looking ahead, an important milestone for Journey Medical is the Prescription Drug User Fee Act (PDUFA) goal date on November 4, 2024. This date is crucial for the approval process of their new drug applications, reflecting the company's ongoing efforts in drug development and commercialization.
For more information, investors and interested parties can contact Jaclyn Jaffe at (781) 652-4500 or via email at ir@jmcderm.com. Media inquiries can be directed to Tony Plohoros at (908) 591-2839 or tplohoros@6degreespr.com.
Journey Medical Corporation (Nasdaq: DERM) reported total revenues of $73.7 million for the full year 2022, reflecting a 17% increase from 2021. The company experienced a 9% decline in Q4 revenue, primarily due to generic competition affecting Targadox. Despite this, SG&A expenses increased due to expanded sales efforts, reaching $59.5 million. The net loss decreased to $29.6 million, or $1.69 per share from $44.0 million in 2021. Journey Medical completed enrollment for its Phase 3 clinical trials for DFD-29 in January 2023, with topline data expected soon. The company plans to file a New Drug Application in the second half of 2023.
Journey Medical Corporation (Nasdaq: DERM) has announced plans to release its year-end 2022 financial results on March 29, 2023, after U.S. market close. The Company will host a conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested parties can join the call by dialing 1-866-777-2509 (U.S.) or 1-412-317-5413 (international) approximately 10 minutes prior to start time. A live audio webcast and replays will be available on the Company’s website. Journey Medical focuses on dermatological pharmaceutical products and is based in Scottsdale, Arizona.
Journey Medical Corporation (Nasdaq: DERM) has completed treatment in its Phase 1 clinical trial of DFD-29, aimed at treating papulopustular rosacea. The trial involved 60 healthy adults and assessed both safety and tolerability, with no significant safety issues reported. Topline results from this trial are expected in the first half of 2023. Additionally, the Phase 3 trials for DFD-29 have been fully enrolled, with data anticipated in the same timeframe, leading to a potential New Drug Application filing later in 2023. Rosacea affects over 16 million Americans, emphasizing the market need for effective treatments.
Journey Medical Corporation (Nasdaq: DERM), a biopharmaceutical company focused on dermatological treatments, will participate in the 35th Annual ROTH Conference from March 12-14, 2023. CEO Claude Maraoui will host a fireside chat on March 14 at 9:30 a.m. PT and will be available for one-on-one meetings. A webcast of the chat will be accessible on Journey Medical's website for 30 days post-event. The company is committed to innovative dermatology products and currently markets eight treatments for common skin conditions. Founded by Fortress Biotech (Nasdaq: FBIO), Journey Medical is headquartered in Scottsdale, Arizona.
FAQ
What is the current stock price of Journey Medical Corporation (DERM)?
What is the market cap of Journey Medical Corporation (DERM)?
What does Journey Medical Corporation do?
What are some of Journey Medical's key products?
What recent achievements has Journey Medical Corporation made?
When is the next conference call for Journey Medical?
What is the PDUFA goal date for Journey Medical?
How can I contact Journey Medical for investor relations?
Who handles media relations for Journey Medical?
What is DFD-29?
Where are Journey Medical's products marketed?
What is the focus of Journey Medical Corporation?
